Navigation Links
Generex Provides Additional Details for October 21st Live Video Webcast
Date:10/20/2010

WORCESTER, Mass., Oct. 20 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) today announced additional details for its live video webcast scheduled for tomorrow, Thursday, October 21, 2010, in New York City.

Joining Mark Fletcher, the Company's Interim President & Chief Executive Officer, for the webcast will be:

  • Dr. Craig Eagle, a member of the Company's Scientific Advisory Board. Dr. Eagle currently serves as Vice-President of Strategic Alliances and Partnerships for the oncology business unit at Pfizer, Inc.
  • Dr. Jerry Bernstein, the Company's Vice-President for Medical Affairs.  Dr. Bernstein is a past President of the American Diabetes Association, an attending physician at Beth Israel Medical Centre, physician emeritus at Lenox Hill Hospital and Montefiore Medical Centre, both in New York City, and a member of the Board of Directors of the American Diabetes Association Research Foundation.
  • Dr. Joseph Rubinfeld, a member of the Company's Scientific Advisory Board (via telephone).  Dr. Rubinfeld is a founder of Amgen Inc. and SuperGen, Inc.
  • Dr. Eric von Hofe, President of the Company's wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (www.antigenexpress.com).
  • George Markus, Vice-President of Regulatory & Scientific Affairs.
  • Robert S. Shea, President & Chief Executive Officer of Global Medical Direct, LLC.
  • Dr. David Brusegard, a consultant to the Company in respect of the insurance and reimbursement and the integration of the Company and Global Medical Direct, LLC.

  • The particulars of the conference are as follows:Date:

    Thursday, October 21, 2010Time:

    1 p.m. EasternWhere:

    NASDAQ Marketsite, Times Square, 43rd & Broadway, NYCTo attend in-person, RSVP absolutely required for building security.  Please contact: '/>"/>

    SOURCE Generex Biotechnology Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
    2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
    3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
    4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
    5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
    6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
    7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
    8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
    9. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
    10. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
    11. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... 2014 Topical BioMedics, Inc., is celebrating ... end their suffering, restoring hope an quality of life ... only possible because of the innovative cellular biomedicines research ... a reality. , The company was founded in ... Paradise (president, chief of research, and Topricin inventor), Aurora ...
    (Date:9/22/2014)... , Sept. 22, 2014 Research ... "Global and Chinese Microcrystalline Cellulose Industry Report 2014" ... Global and Chinese Microcrystalline Cellulose Industry Report 2014 is ... of the global microcrystalline cellulose industry with a focus ... a basic overview of the industry including definitions, classifications, ...
    (Date:9/22/2014)... LANSING, Mich., Sept. 22, 2014  Neogen Corporation (Nasdaq: ... for the first quarter of its 2015 fiscal year, ... increase compared to net income of $7,839,000 in the ... stock split effective Oct. 30, 2013, earnings per share ... a year ago. First quarter revenues increased ...
    (Date:9/22/2014)... , September 22, 2014 ... on a mixed note as the Dow Jones Industrial ... Composite closed at 4,579.79, down 0.30%. The S&P 500 ... trading session, six out of ten sectors finished on ... Index ended the day at 751.48, up 0.10%, with ...
    Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
    ... interesting meeting took place this past week at the University ... The focus of the meeting was an opportunity to hear ... last annual BIO meetings in different cities, as a preview ... this Olympics of Biotechnology meeting comes to Chicago in April, ...
    ... hit a nerve. , , I heard from a number ... 2.0 is spelled b-u-b-b-l-e, and who want none of it. As ... use a healthy dose of caution to prevent the heavy Kool-Aid ... group. , ,Indeed, in dozens of conversations with start-ups seeking a ...
    ... and after its recent redesign The Internal Revenue Service ... well as tweaking its search engine to hopefully make it easier ... keeping roughly the same design since mid-2002, the IRS decided to ... Among other features, the site has links to the most-requested publications ...
    Cached Biology Technology:The legacy of BIO 2006, what it will be and how we need to plan for it now 2The legacy of BIO 2006, what it will be and how we need to plan for it now 3The legacy of BIO 2006, what it will be and how we need to plan for it now 4The legacy of BIO 2006, what it will be and how we need to plan for it now 5The legacy of BIO 2006, what it will be and how we need to plan for it now 6Can we prevent Web 2.0 from being a bubble? 2Can we prevent Web 2.0 from being a bubble? 3
    (Date:9/22/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... mobile commerce market, issues the following corporate shareholder update ... Letter from the CEO : ... funding and joined the NASDAQ to support ramping of ... biometric and authentication products and services. This strategic achievement positions ...
    (Date:9/21/2014)... significantly less likely to report taking iron supplements before ... who are developing normally, a study by researchers with ... iron intake was associated with a five-fold greater risk ... 35 or older at the time of the child,s ... as obesity hypertension or diabetes. , The research is ...
    (Date:9/21/2014)... at the University of California, San Diego, have developed ... that control the activity of genes based on sequences ... from its application to human embryonic cells in a ... 21. , "All of our cells have the same ... said John Whitaker, lead author of the report. "Skin ...
    Breaking Biology News(10 mins):NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Mothers of children with autism less likely to have taken iron supplements 2Program predicts placement of chemical tags that control gene activity 2
    ... Shire plc (LSE: SHP)(NASDAQ: SHPGY ), the ... approved,the scheme of arrangement between Shire plc and ... which becomes effective on 23 May 2008,results in ... SHP,NASDAQ: SHPGY) becoming the new holding company for ...
    ... CORVALLIS, Ore. An international team of scientists surveying ... Coast of North America has discovered for the first ... miles of the shoreline, raising concern for marine ecosystems ... an Oregon State University research vessel, also discovered that ...
    ... called FIGLA cause premature ovarian failure in at least a ... from Baylor College of Medicine in Houston and Shandong University ... the American Journal of Human Genetics. We hope to ... genes associated with this problem to find biomarkers in blood ...
    Cached Biology News:Court Approves Scheme of Arrangement 2Court Approves Scheme of Arrangement 3Pacific coast turning more acidic 2Pacific coast turning more acidic 3Oocyte-specific gene mutations cause premature ovarian failure 2
    ...
    ... SpliceArray service, ExonHit can design custom microarrays ... your gene list. Proprietary algorithms are ... microarray probes from high quality, spliced cDNAs ... event contained in a custom SpliceArray is ...
    ... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
    Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
    Biology Products: